The NeurologyLive® clinical focus page on sleep disorders provides information about the latest FDA actions, clinical guideline updates, clinical trial findings, and interviews with physicians on conditions such as obstructive sleep apnea, cataplexy, narcolepsy, insomnia, excessive daytime sleepiness, and more. The page features podcasts, videos, and news stories about the latest in clinical care for these sleep disorders.
September 1st 2025
Here's some of what is coming soon to NeurologyLive® this week.
Prioritizing Sleep Health in the Modern World of Sleep Disorders: Ana Krieger, MD, MPH
April 1st 2024The medical director of the Center for Sleep Medicine at Weill Cornell Medicine talked about the importance of sleep health in modern life with the increasing prevalence of sleep disorders such as narcolepsy in the United States. [WATCH TIME: 5 minutes]
Sex Dependent Decreases in REM Sleep After TBI and the Impact it May Have on Recovery
March 29th 2024Grace Griesbach, PhD, the national director of clinical research for Centre for Neuro Skills, discussed the impact of REM sleep on memory following traumatic brain injury and the importance of considering sex as a biological variable.
Introducing Sleeping Around the Podcast × NeurologyLive
March 21st 2024Sleeping Around the Podcast is hosted by Anne Marie Morse, DO, FAASM, a neurologist with special qualifications in child neurology and a sleep medicine specialist, who has partnered with NeurologyLive to bring you bite-sized, sleep-focused content.
The Glymphatic Pathway: Evaluating Neurological Conditions From a New Perspective
March 20th 2024This complex waste clearance pathway within the CNS plays a crucial role in maintaining brain homeostasis, as a mechanism of protein waste removal alongside autophagy and protein aggregate ubiquitination.
FDA Issues Complete Response Letter for Vanda Pharmaceuticals' Tasimelteon for Insomnia
March 11th 2024In recent news, the FDA has issued a complete response letter for Vanda Pharmaceuticals' tasimelteon for treating insomnia because of identified deficiencies and cannot be approved in its current form.